article Open AccessTop 1% cited

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Annals of Oncology · 2019 · Vol. 30(8) · pp. 1321–1328

J. Mazieres✉(Université Toulouse III - Paul Sabatier)Alexander Drilon(Memorial Sloan Kettering Cancer Center)Amélie Lusque(Institut Claudius Regaud)Laurent Mhanna(Université Toulouse III - Paul Sabatier)Alexis B. Cortot(Université de Lille)Laura Mezquita(Université Paris-Sud)Alesha A. Thai(Peter MacCallum Cancer Centre)Céline Mascaux(Aix-Marseille Université)S. Couraud(Université Claude Bernard Lyon 1)Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux)Michel M. van den Heuvel(Radboud University Nijmegen)Joel W. Neal(Stanford University)Nir Peled(Soroka Medical Center)Martin Früh(University of Bern)Terry L. Ng(University of Colorado Cancer Center)V. Gounant(Université Claude Bernard Lyon 1)Sanjay Popat(Royal Marsden Hospital)Joachim Diebold(University of Lucerne)Joshua K. Sabari(Memorial Sloan Kettering Cancer Center)Viola W. Zhu(University of California, Irvine)Sacha I. Rothschild(University Hospital of Basel)Paolo Bironzo(University of Turin)Alex Martínez‐Martí(Vall d'Hebron Hospital Universitari)Alessandra Curioni‐Fontecedro(University Hospital of Zurich)Rafael Rosell(Institut Català d'Oncologia)Mickaël Lattuca-Truc(Centre Hospitalier Universitaire de Grenoble)Marcel WieswegBenjamin Besse(Université Paris-Sud)Benjamin Solomon(Peter MacCallum Cancer Centre)Fabrice Barlési(Aix-Marseille Université)Robert D. Schouten(Radboud University Nijmegen)Heather A. Wakelee(Stanford University)D. Ross Camidge(University of Colorado Cancer Center)Gérard Zalcman(Université Claude Bernard Lyon 1)Silvia Novello(University of Turin)Sai‐Hong Ignatius Ou(University of California, Irvine)Julie Milia(Université Toulouse III - Paul Sabatier)Oliver Gautschi(University of Bern)

View via DOI Full-text PDF

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Research StudiesMedicineLung cancerCancer researchImmune checkpointOncologyCancerImmune systemInternal medicineImmunotherapyImmunology

MeSH terms

Antineoplastic Agents, ImmunologicalProgression-Free SurvivalAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedMutationOncogenesRegistries